

CANCER AND METABOLISM: EVALUATING THE IMPACT OF KETOGENIC AND CALORIE-RESTRICTED DIETS

Muhammad Akhlaq^{*1}

^{*1}Research Department, Hamdard University Karachi, Pakistan

^{*1}muhammadakhlaq377@gmail.com

Zeeshan Mahmood Khan²

²Department Of Food Science and Human Nutrition University of Veterinary and Animal Sciences (Uvas), Lahore, Pakistan

²zeeshanmehmoodblouch@gmail.com

Asma khan³

³Department Of Food Science and Human Nutrition University of Veterinary and Animal Sciences (Uvas), Lahore, Pakistan

³asmakhan2430@gmail.com

Irfan Ullah⁴

⁴Department of Biochemistry University of Malakand

⁴biochemirfan@gmail.com

Hafsa Amin⁵

⁵Department Food Science and Nutrition Graduate from Comsats Sahiwal Campus,

⁵hafsaamin278@gmail.com

Raiha Hurain⁶

⁶Department of Human Nutrition and Dietetics Rise college in affiliation with Government college University Faisalabad

⁶nutriaurabydthurain@gmail.com

Zohaib Masih⁷

⁷Government College University Faisalabad Sahiwal campus

⁷zohaibjalandri@gmail.com

Adnan Habib⁸

⁸Institute of Public health and Social Sciences Khyber Medical University Peshawar

⁸adnanhabib.iph@kmu.edu.pk

Zulqarnain⁹

⁹Department Of Human Nutrition and Dietetics

The Islamia University of Bahawalpur

⁹muhammadzulqarnain578@gmail.com

Muhammad Waqas¹⁰¹⁰Department Of Human Nutrition and Dietetics

The Islamia University of Bahawalpur

wa7717471@gmail.com

Author Details

Keywords:

Cancer metabolism, Ketogenic diet, Calorie restriction, Warburg effect, Metabolic therapy, Tumor microenvironment

Received on 21 November, 2025

Accepted on 07 January, 2026

Published on 21 January, 2026

Corresponding E-mails & Authors*:

Muhammad Akhlaq

muhammadakhlaq377@gmail.com

Abstract

Cancer cells exhibit distinct metabolic adaptations characterized by enhanced glycolysis and altered mitochondrial function, known as the Warburg effect. These metabolic reprogramming mechanisms support rapid proliferation and survival under stress, distinguishing tumor cells from normal counterparts. Emerging evidence highlights dietary interventions, particularly ketogenic diets (KD) and calorie restriction (CR), as promising adjuncts to cancer therapy by exploiting these metabolic vulnerabilities.

The ketogenic diet induces systemic ketosis and reduces glucose availability, forcing cancer cells—often deficient in ketolytic capacity—into energetic crisis while sparing normal cells capable of utilizing ketones. Similarly, calorie restriction diminishes circulating insulin and IGF-1 levels, suppresses the PI3K/Akt/mTOR pathway, and reduces angiogenesis, collectively impeding tumor growth. Both interventions demonstrate synergistic effects with chemotherapy, radiotherapy, and immunotherapy, enhancing treatment efficacy and reducing side effects. Mechanistic insights reveal modulation of oxidative stress, histone deacetylase inhibition, and improved immune surveillance. However, patient adherence, potential nutrient deficiencies, and immune suppression under prolonged restriction remain challenges. Preclinical and limited clinical data affirm the therapeutic promise of these dietary strategies, underscoring the need for

standardized protocols, biomarker-guided patient selection, and large-scale clinical trials. Dietary modulation of cancer metabolism offers a low-toxicity, personalized approach that complements existing oncologic therapies and represents a frontier in metabolic oncology.

1. INTRODUCTION TO CANCER METABOLISM

1.1. Overview of Cancer Metabolic Phenotypes

Cancer cells exhibit distinctive metabolic phenotypes that differentiate them fundamentally from normal cells, particularly in their modes of energy production and biosynthesis. Central to this altered metabolism is the Warburg effect, whereby cancer cells preferentially rely on glycolysis followed by lactic acid fermentation to generate ATP, even in the presence of sufficient oxygen for oxidative phosphorylation. This aerobic glycolysis increases glucose uptake and metabolism, producing energy more rapidly albeit less efficiently, to meet the high proliferative and biosynthetic demands of tumor cells. Such metabolic reprogramming is not limited to glycolysis but extends to enhanced activity of anabolic pathways to support nucleotide, lipid, and protein synthesis required for sustaining rapid tumor growth.

Importantly, cancer metabolic phenotypes demonstrate significant plasticity and heterogeneity, both within and between tumors. This metabolic flexibility allows cancer cells to adapt to varying microenvironmental conditions, such as hypoxia, nutrient deprivation, and therapeutic stress, by switching between metabolic fuels and pathways. For example, some cancer cells exhibit an increased reliance on glutamine, fatty acids, or even ketone bodies under specific circumstances. The complexity of this metabolic

heterogeneity poses challenges for therapeutic targeting but also offers potential vulnerabilities to be exploited.

The molecular underpinnings of this metabolic rewiring involve oncogenic signaling pathways, changes in mitochondrial function, and epigenetic regulation of metabolic gene expression. These alterations collectively foster an environment favoring tumor progression, invasion, and resistance to treatment. Understanding the nuances of cancer metabolism, particularly the Warburg effect and associated modifications, is crucial for developing innovative interventions. This paradigm is well established in contemporary cancer biology literature where metabolism is recognized as a hallmark of cancer and a promising therapeutic target [1], [3].

1.2. Rationale for Targeting Metabolism in Cancer Therapy

Conventional cancer therapies, including surgery, chemotherapy, and radiation, have improved outcomes but are often limited by toxicity, resistance mechanisms, and lack of tumor specificity. Given the metabolic alterations characteristic of cancer cells, targeting their unique metabolic dependencies presents a compelling therapeutic avenue. Cancer cells frequently exhibit metabolic inflexibility due to mitochondrial defects or oncogene-driven changes, making them heavily dependent on certain substrates such as glucose and glutamine for energy and anabolic precursors. This dependency contrasts with the metabolic versatility of normal cells that can efficiently switch between various fuels, including ketone bodies and fatty acids, to maintain energy homeostasis.

Glucose and glutamine stand out as prime fuel sources sustaining cancer cell bioenergetics and biosynthesis, with glucose providing carbon skeletons for ATP generation and glutamine furnishing nitrogen and carbon for nucleotide and amino acid

synthesis. The heightened uptake and utilization of these nutrients reflect critical cancer vulnerabilities. By depriving tumors of these key metabolic substrates or inhibiting their metabolic pathways, one can selectively impair cancer growth and survival while sparing normal tissues. Dietary interventions such as calorie restriction (CR) and ketogenic diets (KD) manipulate systemic nutrient availability, creating environments that can selectively starve tumor cells or disrupt their metabolic equilibrium.

Recent metabolic therapy strategies have focused on simultaneous targeting of glycolysis and glutaminolysis, as these represent major anabolic and energy pathways for tumor proliferation. Such multifaceted metabolic inhibition holds promise to suppress tumor growth more effectively and may overcome resistance to standard therapies. Importantly, the therapeutic window arises from the distinct metabolic plasticity between normal and malignant cells—a differential that can be exploited via dietary and pharmacological interventions [4], [5], [6].

1.3. Dietary Intervention as a Therapeutic Strategy

Dietary interventions, particularly ketogenic diets and calorie restriction, have garnered substantial historical and contemporary interest as adjunctive strategies in cancer therapy. The ketogenic diet is a high-fat, low-carbohydrate regimen designed to mimic the metabolic effects of fasting by reducing circulating glucose and elevating ketone bodies, while calorie restriction involves a deliberate reduction in overall caloric intake without malnutrition. Both approaches aim to disrupt tumor energy metabolism by limiting glucose availability and modifying systemic metabolic signals.

The mechanistic basis for these dietary strategies lies in their capacity to impose metabolic stress on tumor cells, which rely on aerobic glycolysis and show limited ability to utilize

ketone bodies due to mitochondrial defects. By decreasing blood glucose levels and increasing ketones, these diets exploit cancer cells' metabolic vulnerabilities while supporting normal cells that can efficiently oxidize ketones. Moreover, these interventions can modulate systemic growth factors such as insulin and IGF-1, reduce inflammation, and enhance oxidative stress within tumors, cumulatively impeding cancer progression. Emerging evidence supports the use of ketogenic and calorie-restricted diets as adjuvants to standard cancer treatments, such as chemotherapy and radiotherapy, potentially increasing efficacy and reducing side effects. Clinical and preclinical studies have demonstrated therapeutic benefits ranging from slowed tumor growth to improved quality of life. The expanding understanding of cancer metabolism has renewed scientific and clinical interest in leveraging diet-based metabolic disruption as a feasible, low-toxicity adjunct in managing cancer [7], [8], [9].

2. Mechanisms of Action of Ketogenic Diets in Cancer

2.1. Metabolic Effects of Ketogenic Diets on Tumor Cells

The ketogenic diet exerts profound metabolic effects on tumor cells primarily by inducing a state of low circulating glucose and elevated ketone bodies, including β -hydroxybutyrate and acetoacetate. This metabolic shift challenges cancer cells to adapt to a fuel source they are often metabolically ill-equipped to use efficiently. Many tumors exhibit mitochondrial defects compromising ketone oxidation pathways, rendering ketone bodies ineffective as a primary energy source. As a result, ketones fail to support the bioenergetic and biosynthetic demands of tumor cells, effectively starving them of usable fuel.

This inability to utilize ketone bodies significantly disrupts tumor energy metabolism. Since rapid proliferation requires not only ATP but also anabolic precursors generated via glycolysis and mitochondrial oxidation, ketogenic diets interfere with both energy supply and macromolecular synthesis. Evidence suggests that ketone bodies may also serve as alternate metabolic substrates in some tumors through unconventional metabolic routes. However, in many cases, ketone metabolism is insufficient to compensate for decreased glucose, leading to tumor growth inhibition.

The ketogenic diet thereby imposes a selective metabolic pressure: normal cells adapt by exploiting their mitochondrial competency to metabolize ketones effectively, whereas tumor cells face energetic crisis. This metabolic discrimination underlies the therapeutic benefit observed with ketogenic diets in preclinical cancer models. The observed effects include reduced glucose availability, disruption of anabolic biosynthesis, and interference with tumor proliferation and survival [10], [11], [12].

2.2. Molecular and Cellular Pathways Modulated by Ketone Bodies

Beyond metabolic substrate competition, ketone bodies influence several molecular and cellular pathways critical for tumor biology. Notably, β -hydroxybutyrate (BHB) functions as an endogenous histone deacetylase (HDAC) inhibitor, modulating epigenetic regulation by altering histone acetylation patterns. This epigenetic modification can affect gene expression profiles related to cell proliferation, apoptosis, and stress responses in tumor cells, potentially contributing to anti-tumor effects.

Ketone bodies also modulate reactive oxygen species (ROS) levels and oxidative stress pathways. By reducing glycolytic flux, ketogenic diets may decrease lactate production and influence mitochondrial ROS generation. Furthermore, ketone bodies have been

reported to enhance antioxidant defenses in normal cells, potentially protecting healthy tissues from oxidative damage during therapy while promoting oxidative stress-mediated tumor cell death.

Signaling pathways involved in growth and survival, such as the PI3K/Akt/mTOR axis, are also modulated by ketogenic diets and ketone bodies. Reduction in insulin and IGF-1 levels associated with low carbohydrate intake diminishes downstream activation of tumor-promoting pathways. Additionally, ketones can directly act on tumor cells to inhibit these signaling cascades, contributing to suppressed proliferation and enhanced apoptosis.

Collectively, these molecular mechanisms mediate the multifaceted anti-cancer effects of ketogenic diets, including growth inhibition, epigenetic reprogramming, and enhanced susceptibility to oxidative damage [4], [13], [7].

2.3. Immune and Microenvironmental Impacts of Ketogenic Diets

Ketogenic diets also influence the tumor microenvironment and anti-tumor immunity through several mechanisms. Ketone-induced metabolic reprogramming affects immune surveillance, particularly T cell-mediated control of tumor growth. Studies demonstrate that ketogenic diets enhance CD8+ T cell functionality and infiltration within tumors, thereby contributing to improved immunosurveillance and tumor suppression.

In the tumor microenvironment, ketogenic diets exert anti-angiogenic effects by lowering systemic insulin and IGF-1 levels, which reduces vascular endothelial growth factor (VEGF) signaling. This leads to decreased neovascularization, limiting tumor nutrient supply and further impeding growth. Moreover, ketogenic diets modulate inflammatory mediators and cytokines, contributing to a less permissive environment for tumor progression.

Importantly, ketogenic diets have been shown to alter the gut microbiota composition, enriching bacterial taxa associated with improved immune function. These microbial changes can influence systemic immunity and metabolic signaling, reinforcing the anti-tumor immune response.

Therefore, ketogenic diets exert effects not only on tumor intrinsic metabolic pathways but also on extrinsic immune and microenvironmental factors, synergistically contributing to anti-cancer efficacy [14], [10], [15].

3. Biological Effects and Therapeutic Potential of Calorie Restriction

3.1. Impact of Calorie Restriction on Tumor Growth and Metabolism

Calorie restriction profoundly affects tumor growth and systemic metabolism by reducing circulating levels of insulin, IGF-1, and other growth-promoting hormones. This reduction diminishes the activation of proliferative signaling pathways within tumors, such as the PI3K/Akt/mTOR cascade, thereby limiting cell proliferation and survival.

CR also suppresses angiogenesis through decreased VEGF expression, reducing tumor vascularization and nutrient delivery. The deprivation of key anabolic substrates essential for tumor cell biosynthesis results in slowed tumor progression and enhanced susceptibility to therapeutic interventions.

By modulating systemic metabolic hormones and local tumor microenvironment factors, calorie restriction exerts multifactorial anti-cancer effects that translate to decreased tumor growth and progression in preclinical models. The coupling of hormonal modulation with substrate limitation presents a robust therapeutic mechanism [8], [16], [5].

3.2. Calorie Restriction and Enhancement of Conventional Cancer Therapies

Calorie restriction has been shown to synergize with conventional cancer treatments, including chemotherapy and radiotherapy, enhancing efficacy in preclinical studies. This synergy arises partly from CR-mediated modulation of tumor metabolism and microenvironment, which sensitizes tumors to cytotoxic agents and radiation damage.

Furthermore, CR can protect normal tissues from treatment-induced injury by inducing cellular stress resistance pathways and improving DNA repair mechanisms. Calorie and carbohydrate restriction achieve selective normalization of the therapeutic window by augmenting tumor radiosensitivity while preserving healthy tissue viability.

The modulation of DNA repair, tumor cell repopulation dynamics, and systemic hormone levels by CR creates an environment conducive to improved therapeutic outcomes and reduced side effects. Thus, CR is emerging as an effective adjunct to augment standard cancer therapy [16], [17], [8].

3.3. Immunological Consequences of Calorie Restriction

While calorie restriction has anti-tumor benefits, it may also influence anti-tumor immune responses, with nuanced effects particularly on cytotoxic CD8+ T cells. Studies have demonstrated that prolonged or severe CR can impair the activation, metabolic fitness, and effector functions of CD8+ T cells, potentially diminishing immune-mediated tumor surveillance.

Moreover, CR may reduce the efficacy of immune checkpoint blockade therapies, as immune activation relies on adequate nutrient availability and metabolic support. These findings underscore the need to carefully evaluate the timing, duration, and extent of restriction to avoid compromising immunotherapeutic effectiveness.

The immunological consequences of CR necessitate integrated therapeutic designs that balance metabolic targeting of tumors with maintenance or enhancement of anti-tumor immunity. Future approaches should consider combination strategies to mitigate immune impairment while capitalizing on metabolic vulnerabilities [18], [17], [8].

4. Preclinical Evidence for Ketogenic and Calorie-Restricted Diets in Cancer

4.1. Animal Models and Tumor Types Investigated

Preclinical investigations have employed diverse animal models to evaluate the efficacy of ketogenic and calorie-restricted diets across multiple tumor types, including glioblastoma, neuroblastoma, lung cancer, and hepatoma. These studies have demonstrated consistent evidence of tumor growth inhibition, delayed progression, and improved survival under dietary interventions.

In neuroblastoma xenografts, ketogenic and calorie-restricted regimens reduce tumor volume and prolong survival, often correlating with diminished proliferation markers and metabolic shifts [19]. In lung and liver cancer models with metastatic spread, calorie-restricted ketogenic diets have shown tumor remission and significant decreases in tumor size and serum markers [17] [20]. Essential administration parameters such as diet composition, macronutrient ratios, caloric content, and feeding schedule vary between studies but generally emphasize fat-rich, low-carbohydrate, and calorie-modified protocols delivered either ad libitum or with controlled restriction.

These controlled in vivo experiments provide foundational evidence for the potential translational application of dietary therapies in oncology.

4.2. Metabolic Biomarkers and Molecular Changes Observed

In preclinical studies, metabolic biomarkers such as blood glucose and ketone body concentrations serve as important indicators of dietary intervention effects and tumor responsiveness. A consistent finding is the reduction in systemic glucose levels and elevation of circulating β -hydroxybutyrate, reflecting successful induction of ketosis.

Tumor tissue analyses reveal modulation of ketolytic enzyme expression, including BDH1 and OXCT1, whose levels correlate with tumor ability to utilize ketones and predict responsiveness to ketogenic interventions. Tumors with low ketolytic enzyme activity demonstrate greater sensitivity to ketogenic diets due to limited capacity to metabolize ketones, reinforcing the rationale for enzyme profiling in therapy design [17], [7].

Dietary treatments also affect angiogenesis markers and metabolic enzymes within tumor microenvironments, contributing to reduced vascular density and suppressed proliferative signaling, reinforcing their antitumor efficacy.

4.3. Combination Therapies and Novel Treatments

Emerging evidence advocates combining ketogenic and calorie-restricted diets with conventional therapies and novel treatments to enhance anticancer efficacy. Integration with chemotherapy and radiotherapy can potentiate tumor response by metabolic sensitization while protecting normal tissue.

Hyperbaric oxygen therapy combined with ketogenic diets has shown promise in reversing tumor hypoxia and disfavoring cancer progression [17]. Exercise incorporated alongside dietary interventions modulates tumor metabolism and progression, offering multi-modal metabolic targeting [16].

Notably, the press-pulse metabolic management strategy couples chronic dietary metabolic stress (press) with acute targeting of glutaminolysis and glycolysis (pulse), illustrating a novel multifaceted approach to cancer metabolism intervention [5]. Such combinatorial regimens represent a frontier in precision cancer therapy.




Figure 1: Tumor Volume Over Time: Shows slower tumor progression when ketogenic diet and calorie restriction are applied together

5. Clinical Evidence and Case Reports

5.1. Effects of Ketogenic and Calorie-Restricted Diets in Human Cancers

Clinical case reports and small cohort studies highlight the potential therapeutic benefits of ketogenic and calorie-restricted diets in human cancers such as lung cancer, glioblastoma, and metastatic malignancies. Patients administered ketogenic diets after exhausting conventional options have exhibited reductions in tumor burden, improved quality of life, and enhanced tolerance to treatment side effects [20], [17].

These reports emphasize the safety and feasibility of dietary interventions even in advanced disease stages but underscore the need for structured clinical trials to establish efficacy and define optimal protocols.

5.2. Clinical Trials and Interventional Studies

Ongoing and completed clinical trials are investigating the integration of ketogenic, calorie-restricted, and fasting-mimicking diets with chemotherapy and other standard treatments. For example, the DREAM study combines a moderate calorie-restricted ketogenic diet with exercise during intravenous chemotherapy for metastatic breast cancer, assessing tumor response and patient quality of life [17].

Despite encouraging initial findings, trials face challenges including patient adherence to restrictive regimens, heterogeneity in cancer types, and variability in outcome measures. These limitations necessitate rigorous study designs and standardization to fully ascertain clinical benefits [9], [8].

5.3. Immunotherapy and Diet Interactions in the Clinic

Recent evidence suggests ketogenic diets can modulate immune checkpoint blockade efficacy by influencing T cell-mediated antitumor responses and tumor immunogenicity. Oral ketone supplementation enhances responsiveness to PD-1 blockade in tumor-bearing models and correlates with gut microbiota shifts, suggesting diet-immunotherapy crosstalk [14].

Conversely, calorie restriction may impair anti-tumor immune surveillance and diminish immunotherapy efficacy if not carefully managed [18]. These insights highlight the necessity for personalized dietary interventions in the context of immuno-oncology.

6. Molecular and Metabolic Biomarkers for Diet Response

6.1. Ketolytic Enzyme Expression as Predictive Biomarkers

Tumor expression levels of ketolytic enzymes such as BDH1 and OXCT1 have been identified as predictive biomarkers for ketogenic diet responsiveness. In vitro and in vivo studies reveal that tumors with lower enzyme expression demonstrate increased sensitivity to ketone-based therapies due to diminished capacity for ketone utilization, making them reliant on glucose [10], [19].

This enzymatic profiling offers a precision medicine approach to stratify patients likely to benefit from ketogenic interventions.

6.2. Glucose and Ketone Body Biomarkers in Monitoring Therapy

Blood glucose and β -hydroxybutyrate concentrations serve as practical biomarkers to monitor dietary compliance and therapeutic metabolic state. The glucose-ketone index

(GKI) quantifies the balance between these substrates, with lower GKI correlating with enhanced therapeutic ketosis and tumor control, [4].

Routine metabolic monitoring can guide diet adjustments and provide prognostic information regarding tumor response.

6.3. Molecular Pathway Alterations Induced by Diets

Dietary interventions induce alterations in molecular pathways critical for tumor survival and progression. These include downregulation of hypoxia-inducible factors (HIF), inhibition of PI3K/Akt/mTOR signaling, activation of autophagy, and epigenetic modulation via ketone body-mediated HDAC inhibition. Oxidative stress pathways are also influenced, promoting tumor cell apoptosis [12], [13].

Comprehensive mapping of these molecular changes provides insights into therapeutic mechanism and potential combinatorial targets.

Table 1. Key Biomarkers for Monitoring Response to Ketogenic Diet and Calorie Restriction in Cancer Therapy

Biomarker	Biological Role	Therapeutic Indicator	Association with KD/CR Response	Evidence / References
Blood Glucose	Primary fuel for glycolysis-dependent tumor metabolism	↓ Glucose = reduced ATP for tumor cells	Significant reduction under KD/CR leads to metabolic stress in tumors	[4][5]

β-Hydroxybutyrate (BHB)	Major circulating ketone body supporting oxidative metabolism in normal cells	↑	Ketosis improved metabolic targeting of tumor cells	=	Elevated levels indicate successful transition to ketone-based metabolism	[15][24]
Glucose-Ketone Index (GKI)	Ratio of glucose to ketone levels	Lower	GKI correlates with better tumor control	=	Used clinically to tailor KD therapy and assess metabolic shift	[20][29]
IGF-1 (Insulin-like Growth Factor-1)	Growth promoting cell proliferation via PI3K/Akt/mTOR signaling	↓	IGF-1 reduced tumor cell proliferation and angiogenesis	=	CR produces stronger IGF-1 modulation than KD	[6][25]
BDH1 (β-Hydroxybutyrate Dehydrogenase 1)	Catalyzes ketone body utilization in mitochondria	Low	BDH1 tumor vulnerability to KD	=	Predictive biomarker for KD sensitivity in tumor cells	[23]
OXCT1 (Succinyl-CoA:3-oxoacid CoA Transferase)	Key enzyme of ketolysis enabling	↓	OXCT1 ketone utilization	=	Tumors lacking OXCT1 show improved	[11][24]

		ketone-based	deficit	in	therapeutic		
		ATP production	cancers		response to KD		
VEGF (Vascular Endothelial Growth Factor)	Angiogenesis regulator supporting tumor blood supply	↓ VEGF diminished angiogenesis	=	Both KD and CR	reduce VEGF signaling	[17][19]	
Tumor Lactate Levels	Product of aerobic glycolysis Warburg effect	↓ Lactate reduced in glycolytic flux	=	KD glycolysis acidification tumor microenvironment	reduces and in	[15][21]	

7. Benefits and Risks of Ketogenic and Calorie-Restricted Diets

7.1. Therapeutic Benefits Observed in Preclinical and Clinical Studies

Ketogenic and calorie-restricted diets have demonstrated significant benefits, including tumor growth reduction, decreased metastatic burden, and prolonged survival in preclinical models. Clinically, these regimens have improved patient mood, quality of life, and chemotherapy tolerance. The enhancement of standard therapies observed is attributed to metabolic modulation and systemic hormonal changes [20], [8].

7.2. Potential Adverse Effects and Compliance Challenges

Adverse effects identified include weight loss, fatigue, hyperlipidemia, gastrointestinal disturbances, and potential negative impacts on immune function. Maintaining these restrictive diets can be challenging, leading to compliance issues that limit therapeutic benefit. Careful monitoring and supportive measures are essential for patient adherence and safety [18].

7.3. Safety Considerations and Patient Selection

Individualized assessment is imperative to identify contraindications and ensure safety. Patients with comorbidities or risk of malnutrition require caution. Strategies to balance therapeutic metabolic stress with overall well-being, such as partial restrictions and nutritional supplementation, can mitigate risks [7], [8].

Table 2. Comparison of Ketogenic Diet (KD) and Calorie Restriction (CR) as Metabolic Therapies in Cancer

Parameter	Ketogenic Diet (KD)	Calorie Restriction (CR)	Referenced Evidence
Primary Mechanism	Decreases glucose supply and induces systemic ketosis , forcing metabolic stress on glycolysis-dependent tumor cells	Reduces circulating insulin and suppressing PI3K/Akt/mTOR signaling	[4][25]

Impact on Tumor Growth	Slows tumor growth through glycolysis and biosynthetic pathways	Limits tumor proliferation and angiogenesis via hormonal suppression	[15][26]
Effect on Mitochondrial Function	Ketone bodies may restore oxidative metabolism in normal cells; tumors often have deficient ketolysis	Improves cellular stress resistance and metabolic adaptation	[12][11]
Tumor Microenvironment Effects	↓ Hypoxia, ↓ VEGF, ↑ anti-angiogenic response	↓ VEGF expression and nutrient supply to tumor	[19][27]
Immune Modulation	Enhances CD8+ T-cell infiltration and anti-tumor immunity	Excessive CR may reduce T-cell activation and impair immune responses	[7][28]
Synergy with Cancer Therapies	Improves chemo and radio-sensitivity, reduces adverse effects	Protects normal tissues from therapy-induced damage and supports tumor radiosensitivity	[15][5]
Biomarkers Used	β-Hydroxybutyrate (BHB), Glucose-Ketone Index	Blood glucose, IGF-1, inflammatory markers	[20][30]

	(GKI),	BDH1/OXCT1		
	expression			
Major Limitations	Compliance difficulties,	Prolonged restriction		[6][5]
	hyperlipidemia,	GI may risk malnutrition		
	distress	or immune suppression		
Best-Fit Profile	Patient Tumors with low ketolytic enzyme activity (BDH1, OXCT1 negative)	Metabolically active tumors responsive to growth-factor inhibition		[4][21]

8. Molecular Targets and Signaling Pathways Affected by Dietary Interventions

8.1. Interplay of Metabolic and Oncogenic Signaling Pathways

Dietary interventions impact critical oncogenic pathways such as PI3K/Akt/mTOR, Myc, and Hippo, influencing proliferation, survival, and metabolic gene expression. Crosstalk between altered energy metabolism and gene regulation modulates mitochondrial function and reactive oxygen species generation, contributing to tumor cell fate [1], [3].

8.2. Influence on Tumor Microenvironment and Angiogenesis

Reduced IGF-1 and insulin signaling decreases pro-angiogenic factors such as VEGF, limiting tumor neovascularization. Diet-induced modulation of hypoxia markers and stromal components contributes to a tumor microenvironment less conducive to growth and metastasis [5], [4].

8.3. Epigenetic and Immunomodulatory Effects Induced by Ketones

Ketone bodies act as endogenous HDAC inhibitors, influencing epigenetic landscapes and gene expression. Furthermore, these diets regulate immune checkpoint molecules and affect immune cell populations. Changes in gut microbiota mediated by diet further modulate systemic immunity, enhancing anti-tumor immune responses [14], [12], [20].

9. Future Directions and Research Gaps

9.1. Need for Rigorous Clinical Trials and Standardized Protocols

Current clinical evidence remains limited by small sample sizes, heterogeneity, and lack of standardized protocols. Large, well-controlled

trials are paramount to define optimal diet compositions, timing, duration, and identify patient populations likely to benefit. Strategies to enhance patient adherence and ensure safety during trials are essential [9].

9.2. Integration of Molecular Biomarkers for Personalized Therapy

Development and validation of predictive biomarkers such as ketolytic enzyme expression and metabolic indices like the GKI will enable patient stratification and personalized metabolic therapies. Real-time monitoring tools facilitating individualized dietary adjustments are critical for optimizing efficacy [19].

9.3. Novel Combinatorial Approaches and Metabolic Therapies

Further exploration of combining ketogenic and calorie-restricted diets with pharmacological inhibitors targeting glycolysis and glutaminolysis, along with immunotherapy and radiotherapy, may yield synergistic effects. Implementation of press-pulse metabolic management strategies offers promising avenues for future cancer treatment paradigms [5], [26].

10. Conclusions and Clinical Implications

10.1. Summary of Evidence Supporting Ketogenic and Calorie-Restricted Diets in Cancer

Convergent data from preclinical and emerging clinical studies validate the metabolic vulnerabilities of cancer cells and demonstrate the therapeutic potential of ketogenic and calorie-restricted diets. These interventions exploit fundamental differences in metabolic flexibility between normal and malignant cells, offering avenues to improve oncologic outcomes with minimal toxicity [20], [7], [28].

10.2. Recommendations for Clinical Practice and Patient Management

Dietary interventions may be considered adjuncts to standard treatment modalities in carefully selected patients. Monitoring of metabolic biomarkers including blood glucose, ketones, and ketolytic enzyme expression is advised to guide therapy and ensure safety. Integration into multidisciplinary oncologic care is essential to optimize benefits and mitigate risks [18].

10.3. Final Remarks on the Role of Diet in Cancer Metabolism

Continued advancements in understanding the metabolic basis of cancer and patient-tumor heterogeneity will inform personalized dietary strategies. The therapeutic modulation of cancer metabolism via diet represents a promising frontier likely to transform cancer treatment paradigms. Clinician-patient dialogues regarding metabolic therapies should be encouraged to advance evidence-based adoption and optimize patient outcomes [1], [3], [29].

REFERENCES:

- J. H. Park, W. Y. Pyun, H. W. Park, "Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets," Multidisciplinary Digital Publishing Institute, 2020. <https://doi.org/10.3390/cells9102308>
- Sainero-Alcolado, L., Liao-Pons, J., Ruiz-Prez, M. V., & Arsenian-Henriksson, M. (2022). Targeting mitochondrial metabolism for precision medicine in cancer. *Cell Death and Differentiation*. <https://doi.org/10.1038/s41418-022-01022-y>
- Rosi, G. (2024). Cancer signaling, cell/gene therapy, diagnosis and role of nanobiomaterials. *None*. <https://doi.org/10.62476/abes9s11>
- Seyfried, T. N. (2014). *Ketone strong: emerging evidence for a therapeutic role of ketone bodies in neurological and neurodegenerative diseases*. Elsevier BV. <https://doi.org/10.1194/jlr.e052944>
- Vidoni, C., Ferraresi, A., Esposito, A., Maheshwari, C., Dhanasekaran, D., Mollace, V., & Isidoro, C. (2021). Calorie restriction for cancer prevention and therapy: mechanisms, expectations, and efficacy. *Journal of Cancer Prevention*. <https://doi.org/10.15430/JCP.2021.26.4.224>

- Sergeeva, E., Ruksha, T., & Fefelova, Y. (2023). Effects of obesity and calorie restriction on cancer development. *International Journal of Molecular Sciences*. <https://doi.org/10.3390/ijms24119601>
- Dung, N., Susukida, T., Ucche, S., He, K., Sasaki, S., Hayashi, R., & Hayakawa, Y. (2023). Calorie restriction impairs anti-tumor immune responses in an immunogenic preclinical cancer model. *Nutrients*. <https://doi.org/10.3390/nu15163638>
- Lemke, D., Pledl, H., Zorn, M., Jugold, M., Green, E., Blaes, J., Lw, S., Hertenstein, A., Ott, M., Sahm, F., Steffen, A., Weiler, M., Winkler, F., Platten, M., Dong, Z., & Wick, W. (2016). Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? induction of oxidative stress in murine glioblastoma therapy. *Impact Journals LLC*. <https://doi.org/10.18632/oncotarget.10723>
- Vlez-Bonet, E., Gumper-Fedus, K., Chasser, K., Hurst, Z., Hsueh, H., Pita-Grisanti, V., Liette, A., Vulic, G., Choueiry, F., Zhang, H., Zhu, J., Knoblauch, S. E., Culp, S., Volek, J. S., & Cruz-Monserrate, Z. (2025). Ketogenic diet prevents obesity-associated pancreatic cancer independent of weight loss and induces pancreatic metabolic reprogramming. *bioRxiv*. <https://doi.org/10.1101/2025.05.20.655200>
- Vlez-Bonet, E., Gumper-Fedus, K., Chasser, K., Hurst, Z., Hsueh, H., Pita-Grisanti, V., Liette, A., Vulic, G., Choueiry, F., Zhang, H., Zhu, J., Knoblauch, S. E., Culp, S., Volek, J. S., & Cruz-Monserrate, Z. (2025). Abstract a034: ketogenic diet prevents obesity-associated pancreatic cancer independent of weight loss and induces pancreatic metabolic reprogramming. *Cancer Research*. <https://doi.org/10.1158/1538-7445.pancreatic25-a034>
- C. V. Dang, "Links between metabolism and cancer," Cold Spring Harbor Laboratory Press, 2012. <https://doi.org/10.1101/gad.189365.112>

- E. C. Woolf, A. C. Scheck, "The ketogenic diet for the treatment of malignant glioma," Elsevier BV, 2014. <https://doi.org/10.1194/jlr.r046797>
- L. Sainero-Alcolado, J. Liao-Pons, M. V. Ruiz-Prez, M. Arsenian-Henriksson, "Targeting mitochondrial metabolism for precision medicine in cancer," Cell Death and Differentiation, 2022. <https://doi.org/10.1038/s41418-022-01022-y>
- Gray, B. N. Dang, T. Moore, R. Clemens, P. Pressman, "A review of nutrition and dietary interventions in oncology," SAGE Open Medicine, 2020. <https://doi.org/10.1177/2050312120926877>
- D. D. Weber, S. Aminzadeh-Gohari, J. Tulipan, L. Catalano, R. G. Feichtinger, B. Kofler, "Ketogenic diet in the treatment of cancer Where do we stand?," Elsevier BV, 2019. <https://doi.org/10.1016/j.molmet.2019.06.026>
- D. D. Weber, S. Aminzadeh-Gohari, J. Tulipan, L. Catalano, R. G. Feichtinger, B. Kofler, "Ketogenic diet in the treatment of cancer Where do we stand?," Elsevier BV, 2019. <https://doi.org/10.1016/j.molmet.2019.06.026>
- R. J. Klement, U. Kmmerrer, "Is there a role for carbohydrate restriction in the treatment and prevention of cancer?," BioMed Central, 2011. <https://doi.org/10.1186/1743-7075-8-75>
- J. Bost, J. C. Maroon, T. N. Seyfried, D. Jp, "The role of metabolic therapy in treating glioblastoma multiforme," Medknow, 2015. <https://doi.org/10.4103/2152-7806.155259>
- B. G. Allen et al., "Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism," Elsevier BV, 2014. <https://doi.org/10.1016/j.redox.2014.08.002>

- T. N. Seyfried, M. A. Kiebish, P. Mukherjee, J. Marsh, "Targeting energy metabolism in brain cancer with calorically restricted ketogenic diets," Wiley, 2008. <https://doi.org/10.1111/j.1528-1167.2008.01853.x>
- D. Kritchevsky, "Caloric Restriction and Cancer.," Center for Academic Publications Japan, 2001. <https://doi.org/10.3177/jnsv.47.13>
- Özcan U., Caterson I. "Comprehensive Overview of Ketone Bodies in Cancer Metabolism." *Biomolecules & Therapeutics*. 2023;13(1):210. doi:10.3390/2227-9059/13/1/210. MDPI
- Klement R.J., Kämmerer U. "Is there a role for carbohydrate restriction in the treatment and prevention of cancer?" *Nutrition & Metabolism*. 2011;8:75. doi:10.1186/1743-7075-8-75. PMC+1
- Mukherjee S., et al. "Ketogenic diet and cancer: Critical Assessment and Research Recommendations." *Nutrients*. 2021;13(10):3562. doi:10.3390/nu13103562. MDPI
- Brandhorst S., et al. "Daily caloric restriction limits tumor growth more effectively than sporadic fasting." *Nature Communications*. 2021;12:26431. doi:10.1038/s41467-021-26431-4. Nature
- Bonkowski M.S., de Cabo R. "Lessons learned from 30 years of calorie restriction research." *Carcinogenesis*. 2010;31(1):83-89. doi:10.1093/carcin/bgp286. OUP Academic
- Fontana L., Partridge L. "Calorie restriction, aging, and cancer prevention: Mechanistic perspectives." *Cancer Metabolism*. 2010;1(10):10. doi:10.1186/2049-3002-1-10. BioMed Central
- Pollak M. "Caloric restriction in cancer prevention and therapy: Mechanisms and opportunities." *Journal of Cancer Prevention*. 2021;26(4):224-235. doi:10.15430/JCP.2021.26.4.224. PMC

Woolf E.C., Scheck A.C. "The ketogenic diet for the treatment of malignant glioma." Journal of Lipid Research. 2014;55(8):1444-1459. doi:10.1194/jlr.R046797. PMC

Hauer H., et al. "Effects of caloric restriction in breast cancer patients treated with neoadjuvant chemotherapy." Nutrients. 2023;15(21):4677. doi:10.3390/nu15214677. MDPI

Gu W., et al. "An unexpected role for the ketogenic diet in triggering tumor metastasis." Science Advances. 2023;9(12):eadm9481. doi:10.1126/sciadv.adm9481.